To evaluate the incidence of cataract surgery in patients treated with Mirvetuximab soravtansine (MIRV) and assess long-term ocular safety from January 2021 to December 2023.
Key Findings:
Cataract surgery was performed in 42.3% of patients exposed to MIRV compared to 11.5% in non-exposed patients (P < .001; adjusted odds ratio [aOR] 12.61).
Adding one treatment cycle of MIRV was associated with a 21% increased odds of cataract surgery (aOR 1.21).
64% of patients treated with MIRV for 6 or more months underwent cataract surgery.
Interpretation:
The high incidence of cataract surgery in patients treated with MIRV suggests potential delayed long-term ocular toxic effects, warranting further investigation into the mechanisms and implications.
Limitations:
Retrospective single institution study with a small sample size, which may limit generalizability.
Potential underreporting of cataracts in the non-exposed group due to fewer eye examinations, which could affect the perceived incidence.
Conclusion:
The study highlights the need for further research on delayed ocular toxic effects in patients treated with MIRV, given the significant incidence of cataract surgery observed, which may differ from previous reports.
by Jordyn F. Silverstein, Alexandra Smick, Edmund Tsui, Oladunni Alomaja, Bridget Johnson, Chi-Hong Tseng, Ritu Salani, Dennis J. Slamon, Dana M. Chase, Gottfried E. Konecny
